University of California
Welcome,         Profile    Billing    Logout  
 16 Trials 
48 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tewari, Krishnansu S
OnPrime, NCT05281471: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (, GOG-3076)

Recruiting
3
186
US
olvimulogene nanivacirepvec, GL-ONC1 and GLV-1h68, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar)
Genelux Corporation, GOG Foundation
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
08/25
10/26
ENGOT-EN20, NCT05611931 / 2022-002540-42: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
ZN-c3-004, NCT04814108: A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma

Recruiting
2
76
Canada, US, RoW
ZN-c3, azenosertib, KP-2638
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Uterine Serous Carcinoma
11/24
05/25
DENALI, NCT05128825: A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Active, not recruiting
2
102
Europe, US, RoW
ZN-c3, azenosertib
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
04/25
10/25
GROINSS-VIII, NCT05076942 / 2016-003973-16: Groningen International Study on Sentinel Nodes in Vulvar Cancer-III

Recruiting
2
157
Europe, US
Radiotherapy combined with cisplatin, chemotherapy, Cisplatin
University Medical Center Groningen, Dutch Cancer Society, NRG Oncology
Vulvar Cancer, Sentinel Lymph Node, Lymph Node Metastases
01/28
01/29
NCT04381650 / 2020-004325-23: A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
49
Europe, Japan, US, RoW
TAK-981, Pembrolizumab
Takeda, Takeda Development Center Americas, Inc.
Advanced or Metastatic Solid Tumors
11/25
11/25
NCT02521844: A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours

Active, not recruiting
1
89
US, RoW
ETC-1922159, Pembrolizumab
EDDC (Experimental Drug Development Centre), A*STAR Research Entities, PPD DEVELOPMENT, LP
Solid Tumors
10/24
10/24
Goyal, Namita
COURAGE-ALS, NCT04944784 / 2020-004040-29: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Terminated
3
489
Europe, Canada, US, RoW
Reldesemtiv, Placebo
Cytokinetics
Amyotrophic Lateral Sclerosis
07/23
07/23
COURAGE OLE, NCT05442775 / 2021-004727-33: A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

Terminated
3
71
Europe, Canada, US, RoW
Reldesemtiv
Cytokinetics, Cytokinetics Inc
Amyotrophic Lateral Sclerosis
06/23
06/23
COMBAT-ALS, NCT04057898 / 2019-003549-14: Evaluation of MN-166 (ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients with ALS

Recruiting
2/3
230
Canada, US
MN-166, ibudilast, placebo
MediciNova
Amyotrophic Lateral Sclerosis
12/25
12/26
NCT06450886: Long-term Extension Study of Ulviprubart (ABC008) in Subjects with Inclusion Body Myositis

Active, not recruiting
2/3
270
US, RoW
Ulviprubart (ABC008)
Abcuro, Inc.
Inclusion Body Myositis (IBM)
01/29
04/29
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Active, not recruiting
2/3
231
Europe, Canada, US, RoW
ABC008
Abcuro, Inc., Syneos Health
Inclusion Body Myositis
11/25
12/25
NCT04993755 / 2021-002251-11: A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

Active, not recruiting
2a
42
Europe, US
TPN-101, 400 mg/day, Placebo
Transposon Therapeutics, Inc., Transposon Therapeutics, Inc
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
09/23
09/23
EPISOD1, NCT06100276: Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

Recruiting
1/2
20
US
AMT-162
UniQure Biopharma B.V.
Amyotrophic Lateral Sclerosis
09/26
03/31
CNMAu8.EAP02, NCT05281484: Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and for ALS

Available
N/A
US
CNM-Au8, Nanocrystalline gold
Clene Nanomedicine
Amyotrophic Lateral Sclerosis
 
 
CAPTURE, NCT03489278: Clinical Procedures to Support Research in ALS

Recruiting
N/A
1200
US
University of Miami, Muscular Dystrophy Association, National Institute of Neurological Disorders and Stroke (NINDS), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH)
Amyotrophic Lateral Sclerosis, ALS-Frontotemporal Dementia, Primary Lateral Sclerosis, Progressive Muscular Atrophy
06/25
06/25
INSPIRE-IBM, NCT05046821: Sporadic Inclusion Body Myositis Natural History Study

Active, not recruiting
N/A
150
US
University of California, Irvine, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Sporadic Inclusion Body Myositis, Inclusion Body Myositis
01/26
01/26
Mozaffar, Tahseen
Fortify, NCT05775848: Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)

Active, not recruiting
3
81
Europe, US, RoW
BBP-418 (ribitol), Placebo
ML Bio Solutions, Inc.
Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
07/27
07/27
ALKIVIA+, NCT05979441: A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults with Active Idiopathic Inflammatory Myopathy

Enrolling by invitation
3
240
Europe, US, RoW
EFG PH20 SC
argenx
Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
09/27
09/27
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.

Recruiting
2/3
240
Europe, Canada, Japan, US, RoW
EFG PH20 SC, PBO
argenx, argenx BV
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
12/26
02/27
NCT04886518: Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1

Hourglass Jul 2022 - Dec 2022 : Efficacy and safety data for treatment of EDS in patients with Myotonic Dystrophy Type 1
Active, not recruiting
2
30
Canada, US
Pitolisant Oral Tablet, Placebo oral tablet
Harmony Biosciences, LLC
Myotonic Dystrophy 1, Excessive Daytime Sleepiness
10/23
10/24
NCT04146051: Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

Recruiting
2
30
Canada, US
Descartes-08
Cartesian Therapeutics
Myasthenia Gravis, Generalized
03/25
03/26
NCT05669014: A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)

Active, not recruiting
2
12
Europe, US, RoW
Daxdilimab, HZN-7734, Placebo
Amgen
Idiopathic Inflammatory Myositis
03/25
10/25
RESET-Myositis, NCT06154252: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

Recruiting
1/2
24
Europe, US
CABA-201 following preconditioning with fludarabine and cyclophosphamide
Cabaletta Bio
Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Juvenile Dermatomyositis, Juvenile Polymyositis, Juvenile Idiopathic Inflammatory Myopathy (JIIM), Juvenile Myositis
07/28
07/28
NCT05517603: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients

Completed
1/2
25
US
AJ201, JM17, Placebo
AnnJi Pharmaceutical Co., Ltd.
Spinal and Bulbar Muscular Atrophy, Kennedy's Disease
04/24
04/24
FORTIS, NCT04174105: Gene Transfer Study in Patients With Late Onset Pompe Disease

Recruiting
1/2
18
Europe, US
zocaglusagene nuzaparvovec, AT845
Astellas Gene Therapies
Pompe Disease (Late-onset)
11/29
11/29
LION-CS101, NCT05230459: A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)

Recruiting
1/2
10
US
AB-1003 dose level 1, AB-1003 dose level 2, Placebo
Asklepios Biopharmaceutical, Inc.
Limb Girdle Muscular Dystrophy, Limb-Girdle Muscular Dystrophy Type 2, LGMD2I, Muscular Dystrophy, LGMD2, LGMD, FKRP, FKRP Mutation, Fukutin Related Protein
12/28
12/28
NCT04093349 / 2019-001283-30: A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)

Active, not recruiting
1/2
4
Europe, Canada, US
SPK-3006
Spark Therapeutics, Inc.
Pompe Disease, Pompe Disease (Late-onset), Glycogen Storage Disease Type 2, Glycogen Storage Disease Type II, LOPD, Lysosomal Storage Diseases, Acid Maltase Deficiency
04/32
04/32
GRASP-01-002, NCT05257473: Defining Endpoints in Becker Muscular Dystrophy

Recruiting
N/A
80
Europe, US, RoW
Virginia Commonwealth University, Edgewise Therapeutics, Inc.
Becker Muscular Dystrophy, Muscular Dystrophies, Muscular Dystrophy in Children, Muscular Dystrophy, Becker
05/25
05/26
GRASP, NCT03981289: Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD)

Active, not recruiting
N/A
80
Europe, US
Virginia Commonwealth University, Newcastle University, Nationwide Children's Hospital, Washington University School of Medicine, University of Iowa, University of Minnesota, University of California, Irvine, Hugo W. Moser Research Institute at Kennedy Krieger, Inc., University of Colorado, Denver, University of Kansas Medical Center
Limb Girdle Muscular Dystrophy, Muscular Dystrophies
06/25
06/25
INSPIRE-IBM, NCT05046821: Sporadic Inclusion Body Myositis Natural History Study

Active, not recruiting
N/A
150
US
University of California, Irvine, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Sporadic Inclusion Body Myositis, Inclusion Body Myositis
01/26
01/26
GRASP-01-003, NCT05618080: LGMD R1 Natural History Study

Recruiting
N/A
100
Europe, US
Virginia Commonwealth University, Nationwide Children's Hospital, Washington University School of Medicine, University of Iowa, University of Florida, University of Minnesota, Newcastle University, University of Kansas Medical Center, University of Colorado, Denver, Indiana CHC (Community Health Clinic), University of California, Irvine
Calpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2A, Limb Girdle Muscular Dystrophy, Limb Girdle Muscular Dystrophy Type R1, LGMD2A
05/28
08/28
Wong, Sandy
NCT04549363: Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin

Terminated
3
16
US
Belantamab mafodotin
GlaxoSmithKline
Multiple Myeloma
11/22
11/22
ALTITUDE, NCT05486481: Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14)

Recruiting
1/2
46
US
Venetoclax, Venclexta, Dexamethasone, Ozurdex, Daratumumab, Darzalex, Daratumumab SC, Cyclin D1 gene (CCDN1) /immunoglobulin heavy chain (IGH) fluorescence in situ hybridization (FISH) assay
Alfred Chung, MD, Janssen Pharmaceuticals, AbbVie
AL Amyloidosis, Light Chain (AL) Amyloidosis, Systemic Light Chain Disease
12/27
12/27
NCT04754945: Isatuximab As Upfront Therapy for the Treatment of High Risk AL Amyloidosis

Active, not recruiting
1
11
US
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Isatuximab, Hu 38SB19, Isatuximab-irfc, SAR 650984, SAR650984, Sarclisa
Emory University, Sanofi, National Cancer Institute (NCI)
AL Amyloidosis
07/25
07/26
NCT04615572: Screening to Improve Survival in AL Amyloidosis

Completed
N/A
35
US
Tufts Medical Center, National Institute on Aging (NIA)
Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
07/23
07/23
NCI-2022-03845, NCT05362331: Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy

Withdrawn
N/A
20
NA
Web Application, Companion for CAR-T Web Application, CAR-T Web Application (CC), CAR-T Web App
University of California, San Francisco
Lymphoma, Leukemia, Plasma Cell Dyscrasia
06/25
06/25
Habib, Ali A
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Recruiting
3
235
Europe, Canada, Japan, US, RoW
Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918
Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
05/25
03/28
RESET-MG, NCT06359041: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

Recruiting
1/2
12
US
CABA-201
Cabaletta Bio
Generalized Myasthenia Gravis (gMG)
09/29
09/29
NCT06704269: Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

Recruiting
1/2
15
Japan, US
YTB323
Novartis Pharmaceuticals
Generalized Myasthenia Gravis
08/29
08/29
NCT06106672: Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

Recruiting
1/2
54
US
CNP-106, Placebo
COUR Pharmaceutical Development Company, Inc.
Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis, MuSK MG
06/26
08/26
NCT05451212: Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis

Recruiting
1
24
US
MuSK-CAART
Cabaletta Bio
MuSK Myasthenia Gravis
10/28
10/28
IMC for ALS, NCT05104710: Intermuscular Coherence as a Biomarker for ALS

Recruiting
N/A
650
US
University of Chicago, National Institutes of Health (NIH), Massachusetts General Hospital, Washington University School of Medicine, University of California, Irvine, National Institute of Neurological Disorders and Stroke (NINDS)
Amyotrophic Lateral Sclerosis
06/25
12/25
EXPLORE-MG2, NCT06002945: Exploring Outcomes and Characteristics of Myasthenia Gravis 2

Active, not recruiting
N/A
400
US
Blood sample
Yale University, National Center for Advancing Translational Sciences (NCATS), National Institute of Neurological Disorders and Stroke (NINDS)
Myasthenia Gravis
12/26
12/26
Gaid, Pola
COMBAT-ALS, NCT04057898 / 2019-003549-14: Evaluation of MN-166 (ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients with ALS

Recruiting
2/3
230
Canada, US
MN-166, ibudilast, placebo
MediciNova
Amyotrophic Lateral Sclerosis
12/25
12/26
HEALEY ALS, NCT04297683: Platform Trial - Master Protocol

Active, not recruiting
2/3
1500
US
ABBV-CLS-7262, DNL343
Merit E. Cudkowicz, MD, Massachusetts General Hospital
Amyotrophic Lateral Sclerosis
07/25
04/26
NCT05517603: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients

Completed
1/2
25
US
AJ201, JM17, Placebo
AnnJi Pharmaceutical Co., Ltd.
Spinal and Bulbar Muscular Atrophy, Kennedy's Disease
04/24
04/24

Download Options